www.m-ventures.com Open in urlscan Pro
138.201.36.43  Public Scan

Form analysis
0 forms found in the DOM

Text Content

 * About Us
 * Portfolio
   * Actithera
   * Akili
   * Altoida
   * Alcan Systems
   * Ambrx
   * Anavo
   * Apogen Biotechnologies
   * Artios
   * Asceneuron
   * aveni
   * Biolinq
   * Bird Rock Bio
   * Calypso Biotech
   * Celestial.AI
   * DNA SCRIPT
   * Electroninks
   * EpiTherapeutics
   * F-Star
   * Ferroelectric Memory GmbH
   * Forendo Therapeutics
   * Formo
   * FoRx Therapeutics
   * Future Fertility
   * Galecto Biotech
   * IKAS
   * Immunitas
   * Immunorizon
   * Indi molecular
   * Inthera
   * iOmx Therapeutics
   * iOnctura
   * Lumiode
   * Macrophage Pharma
   * Medisafe
   * MemryX
   * Metabomed LTD
   * Metalenz
   * micropsi industries
   * mosa meat
   * Multitude Therapeutics
   * nanoSyrinx
   * Neurable
   * Neviah Genomics
   * ObsEva
   * Neologic
   * Padlock Therapeutics
   * Pantheon Bioscience
   * Peratech
   * Pictor Labs
   * Pilltracker
   * Plexium
   * Prexton Therapeutics
   * Progyny
   * PxE
   * Rewind Therapeutics
   * ribometrix
   * Riffyn
   * SciPio Bioscience
   * SeeQC
   * Sentaur Biosciences
   * Sonde Health
   * Soteria
   * Synaffix BV
   * TIGNIS
   * Stealth Company
   * Storm Therapeutics
   * SynSense
   * Theolytics
   * TocopherX
   * RaNA Therapeutics now Translate Bio
   * Vaximm
   * Wiliot
   * x.ilio Therapeutics
 * Team
   * Cheryl Zimberlin
   * Javier Rodriguez
   * Therese Liechtenstein
   * Christian Uhrich
   * Noga Yerushalmi
   * Sebastian Schoefer
   * Christian Patze
   * Anique ter Braake
   * Daniel Franke
   * Bauke Anninga
   * Sarah Luppino
   * Robert Even
   * Jonathan Nash
   * Nadiya Ishnazarova
   * Sandie McCulloch
   * Leonie Willemse
   * Hakan Goker
   * Owen Lozman
 * News
   * Portfolio
   * Archive News
   * Archive Events
 * Contact
   * MS Ventures, Amsterdam
   * MS Ventures, Darmstadt
   * MS Ventures, Cambridge
   * BioIncubator, Israel


ABOUT US

M Ventures is the strategic, corporate venture capital arm of Merck

From its headquarters in the Netherlands and offices in Germany, USA and Israel,
M Ventures invests globally in transformational ideas driven by innovative
entrepreneurs. Taking an active role in its portfolio companies, M Ventures
teams up with management teams and co-investors to translate scientific
discoveries into commercial success. M Ventures focuses on identifying and
financing novel solutions to some of the most difficult challenges, through
company creation and equity investments in fields that will impact the vitality
and sustainability of Merck’s current and future businesses.



FUND

Since inception, M Ventures has been instrumental in the creation and progress
of over 80 global companies, helping advance multiple medicines and technologies
to market launch. M Ventures invests, with dual strategic and financial foci,
into visionary companies that find new ways to: treat the most challenging
diseases, empower scientists with cutting-edge research and development tools,
develop new solutions that change the way in which information is accessed,
stored, processed, and displayed and address some of the most complex challenges
in sustainability and technology convergence.

The fund has the mandate to invest in four focus areas: Healthcare, Life
Sciences, Electronics and Frontier Tech and Sustainability, in alignment with
the strategic interests of Merck’s business areas.


BIOTECHNOLOGY

The M Ventures Biotechnology team executes and manages investments across a
broad range of Healthcare and Life Sciences opportunities.

HEALTHCARE

In Healthcare, we focus on investments in emerging biotechnology companies that
aim to develop differentiated products, platforms, modalities and/or
technologies that have the potential to significantly improve patient outcomes.
Further, the team also creates and manages potential spin-off/spin-out companies
from Merck.

LIFE SCIENCES

In Life Sciences, we are instrumental in building world class Life Science
companies that develop tools, technologies and/or services that have the
potential to make academic and industrial research, chemical/biotech
manufacturing or other biotechnology applications significantly easier and more
efficient to increase success rates of such industries.

The Biotechnology team additionally manages M Ventures’ Israel Bioincubator,
whose aim is to help advance innovative and maturing academic research towards
well financed independent and global companies. The Bioincubator focuses on
company creation, early-stage investments, and is a state of the art home to
multiple M Ventures portfolio companies.


TECHNOLOGY

The M Ventures Technology team executes and manages investments across a broad
range of Electronics, Frontier Technology and Sustainability focused
opportunities.

ELECTRONICS

Discovering and unleashing the most innovative startups in the Electronics
sector, the fund targets companies developing applications and solutions for the
future of computing, data storage, display and device miniaturization.

FRONTIER TECH AND SUSTAINABILITY

This fund exists to pursue interdisciplinary approaches with opportunities that
serve multiple business sectors or have a strong element of technology
convergence. The Frontier Tech and Sustainability fund is looking for novel
technologies, services and business models that can positively impact the
sustainability of both Merck and our customers, be that via novel production of
materials or through innovations in the application of digital technologies.

Imprint
Terms of Use
Privacy Statement
© M Ventures, Amsterdam, The Netherlands